Search Within

Andrew D Seidman

Formats
  1. Journal Article (175)
  2. Meeting Abstract (123)
  3. Conference Paper (9)
  4. Correspondence (3)
  5. Review (3)
  6. Book Section (2)
  7. Research Letter (2)
  8. Editorial (1)
Groups
  1. Breast Medicine Service (318)
  2. Department of Medicine (318)
  3. Solid Tumor Oncology Division (318)
  4. Survivorship Research (158)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (116)
  6. Epidemiology and Biostatistics (84)

More Groups

People
  1. Clifford Hudis (116)
  2. Larry Norton (99)
  3. Teresa Gilewski (38)
  4. Monica Fornier (37)
  5. Gabriella D'Andrea-Carlino (36)
  6. Violante Currie (32)

More People

Years
  1. 2025 (3)
  2. 2024 (4)
  3. 2023 (10)
  4. 2022 (6)
  5. 2021 (9)
  6. 2020 (6)

More Years

Publications
  1. Journal of Clinical Oncology (83)
  2. Breast Cancer Research and Treatment (25)
  3. Cancer Research (23)
  4. Clinical Breast Cancer (19)
  5. Seminars in Oncology (16)
  6. Oncology (Norwalk) (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (84)
  2. Elsevier Inc. (55)
  3. Springer (40)
  4. American Association for Cancer Research (36)
  5. Oxford University Press (29)
  6. C M P Medica LLC * The Oncology Group (14)

More Publishers

Results (318)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs. treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)
    Meeting Abstract

    Tripathy, D.; Tolaney, S. M.; Seidman, A. D.; Anders, C. K.; Ibrahim, N. K.; Rugo, H. S.; Twelves, C.; Diéras, V.; Mueller, V.; Hannah, A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Activity of tesetaxel, an oral taxane, given as a single-agent in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC) in a phase 2 study
    Meeting Abstract

    Seidman, A. D.; Schwartzberg, L. S.; Gudena, V. K.; Rubin, P.; Kroll, S.; O'Connell, J. P.; Tang, K.; O'Shaughnessy, J.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC)
    Meeting Abstract

    O'Shaughnessy, J.; Piccart-Gebhart, M. J.; Schwartzberg, L. S.; Cortes, J.; Harbeck, N.; Im, S. A.; Rugo, H. S.; Untch, M.; Yardley, D. A.; Bondarenko, I.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase I study of intermittent high-dose lapatinib alternating with capecitabine for HER2-positive breast cancer with central nervous system metastases
    Meeting Abstract

    Morikawa, A.; Pentsova, E.; Kemeny, M.; Patil, S.; Li, B. T.; Tang, K.; Fleisher, M.; Van Poznak, C. H.; Norton, L.; Seidman, A. D.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients
    Meeting Abstract

    Bao, T.; Seidman, A. D.; Piulson, L.; Chen, X.; Vickers, A. J.; Vertosick, E.; Blinder, V. S.; Zhi, W. I.; Li, Q. S.; Vahdat, L. T.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Impact of prior systemic therapy on lymphocytic infiltration in surgically resected breast cancer brain metastases
    Meeting Abstract

    Bacotti, A.; Wang, R.; Deal, A. M.; Prince, G.; McKee, M. J.; Moschos, S. J.; Brogi, E.; Morikawa, A.; Anders, C. K.; Seidman, A. D.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • ATTAIN: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)
    Meeting Abstract

    Tripathy, D.; Tolaney, S. M.; Seidman, A. D.; Anders, C. K.; Ibrahim, N. K.; Rugo, H. S.; Twelves, C. J.; Dieras, V.; Müller, V.; Hannah, A. L.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Phase 2 study of dose-dense doxorubicin and cyclophosphamide followed by eribulin mesylate with or without prophylactic growth factor for adjuvant treatment of early-stage human epidermal growth factor receptor 2–negative breast cancer
    Journal Article

    Cadoo, K. A.; Kaufman, P. A.; Seidman, A. D.; Chang, C.; Xing, D.; Traina, T. A.
    Clinical Breast Cancer (2018)

    Fulltext@MSK | Save
  • National Cancer Institute Breast Cancer Steering Committee working group report on meaningful and appropriate end points for clinical trials in metastatic breast cancer
    Journal Article

    Seidman, A. D.; Bordeleau, L.; Fehrenbacher, L.; Barlow, W. E.; Perlmutter, J.; Rubinstein, L.; Wedam, S. B.; Hershman, D. L.; Fallas Hayes, J.; Pearson Butler, L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel and dasatinib in metastatic breast cancer
    Journal Article

    Morris, P. G.; Rota, S.; Cadoo, K.; Zamora, S.; Patil, S.; D'Andrea, G.; Gilewski, T.; Bromberg, J.; Dang, C.; Dickler, M.; more...
    Clinical Breast Cancer (2018)

    Fulltext@MSK | Save